Introduction {#s1}
============

Three randomized trials have shown that male circumcision (MC) reduces the risk of male HIV acquisition in men by 50%--60% \[[@pmed-0050116-b001]--[@pmed-0050116-b003]\]. This finding suggests that the procedure may be an important means of HIV prevention in areas where circumcision is uncommon and where most HIV transmission is due to heterosexual intercourse. The World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) has now recommended that MC be promoted as an additional important strategy for preventing heterosexual HIV infection in men \[[@pmed-0050116-b004]\]. The safety of surgery is a paramount consideration in planning future circumcision programs, both to minimize surgical risks and to provide guidelines for best practices in surgical procedures and postoperative care. Although information is available on postoperative complications in children and in HIV-negative men \[[@pmed-0050116-b001]--[@pmed-0050116-b003],[@pmed-0050116-b005]--[@pmed-0050116-b008]\], there is little information on the safety of circumcision in HIV-infected men \[[@pmed-0050116-b003]\]; this presents an important programmatic issue since future circumcision services are likely to attract both HIV-infected and -uninfected men. Moreover, WHO/UNAIDS guidelines recommend that circumcision be provided to HIV-positive men if medically indicated or if they request the procedure. If surgery were to be unsafe in HIV-positive men, these individuals might have to either be excluded from adult MC programs, which would be potentially stigmatizing, or they might require specialized services for postoperative care, which could add to program costs and complexity.

We conducted two randomized trials of MC in rural Rakai district of southwestern Uganda. One trial, supported by the United States NIH, enrolled HIV-negative men \[[@pmed-0050116-b001]\]. This trial was stopped for efficacy on December 12, 2006. The other trial, which was supported by the Bill & Melinda Gates Foundation, enrolled HIV-positive men, and enrollment was closed on December 19, 2006. In this paper we report on the safety of circumcision in HIV-negative and HIV-positive men enrolled into the intervention arms of these two trials.

Methods {#s2}
=======

The Rakai trials enrolled uncircumcised men aged 15--49 y who provided informed consent for screening and for randomization to immediate circumcision (the intervention arm), or circumcision delayed for 24 m (the control arm). The profile of the two parallel trials is provided in [Figure 1](#pmed-0050116-g001){ref-type="fig"}, and details of trial design are reported elsewhere \[[@pmed-0050116-b001],[@pmed-0050116-b009]\] and described in [Texts S1](#pmed-0050116-sd001){ref-type="supplementary-material"} and [S2](#pmed-0050116-sd002){ref-type="supplementary-material"}. In brief, 6,461 consenting men were screened. If they were HIV-negative, had no contraindications against or medical indications for surgery, and accepted voluntary counseling and testing (VCT), they were enrolled into an NIH-funded trial of HIV-negative men. Men who were HIV-infected at screening, who did not have symptoms of AIDS (WHO stages I or II) or CD4 count \< 350 cells/mm^3^, and who did not have contraindications to or indications for MC, were offered VCT and were enrolled into a Gates Foundation-funded trial. There were 540 screened men who were ineligible for either trial or who failed to complete enrollment and were excluded. The trials were conducted in 50 rural communities of southwestern Uganda, thus enrollment and follow-up were decentralized, but all surgery took place in fully equipped outpatient theaters located in a central facility.

![Profile of Trials for HIV-Positive and HIV-Negative Participants\
fu, follow up.](pmed.0050116.g001){#pmed-0050116-g001}

In the NIH-supported trial, the primary end points were safety and HIV acquisition. A total of 2,474 participants were randomized to receive immediate circumcision. Of these, 2,328 (94.1%) received surgery within 6 m of enrollment, which was completed in August 2005. Two seronegative men who subsequently seroconverted were found to be PCR positive but antibody negative at enrollment and are excluded from the analysis, leaving 2,326 HIV-negative men who received circumcision surgery. The Gates Foundation-supported trial enrolled 925 HIV-positive men, and the primary endpoints for male participants were safety and sexually transmitted infection effects. Of these 925 HIV-positive men, 474 were randomized to immediate circumcision and 420 (88.6%) had received surgery by December 19, 2006, when enrollment was closed. The Gates Foundation trial Data Safety Monitoring Board (DSMB) closed enrollment of HIV-positive men because the NIH trial was stopped for efficacy on December 12, 2006, and it was no longer feasible to mask the HIV status of new HIV-positive participants, (since HIV-negative men could no longer be randomized to the control condition). At enrollment, 864/925 (93.4%) of circumcised HIV-positive men accepted VCT.

Enrollment and follow-up procedures were identical for HIV-positive and HIV-negative men. All men provided written informed consent for screening and trial enrollment. Men randomized to the intervention arm in either trial provided written informed consent for surgery, which described the procedure, risks of surgery, and the requirements for postoperative wound care (e.g., personal hygiene, keeping the wound dry, and recognizing signs of complications), and they were strongly advised to refrain from sexual intercourse until the wound was certified to be fully healed. Men were also advised to practice safe sex, including as appropriate sexual abstinence, monogamy with an uninfected partner, and consistent condom use. Attempts were made to contact spouses of male participants, and these female partners were also instructed on wound care, the need for sexual abstinence until wound healing was certified, and were counseled on the subsequent practice of safe sex. Free condoms were offered to all participants. Free individual and couples counseling was also offered to all participants and their spouses.

All participants had a medical examination, and any penile pathology such as genital ulcerative disease (GUD), discharge, or balanitis were treated prior to surgery. Circumcision was performed by trained physicians in fully equipped outpatient operating theaters. The physicians had completed an internship and were trained by the senior urologist (SW). Training consisted of initially observing surgeries and conducting a minimum of 15 supervised procedures prior to certification of competence. The sleeve circumcision procedure was used: details of surgery are provided in the paper reporting the results of the NIH-supported trial in HIV-negative men \[[@pmed-0050116-b001]\]. All men (HIV-positive or HIV-negative) received the same surgical procedure and postoperative care. Postoperative follow-up visits were scheduled at 24--48 h, 5--9 d, and 4--6 wk. Men could access care at any time if complications occurred between scheduled visits. Follow-up was conducted by health workers (clinical officers and nurses) who were trained to diagnose and treat complications or to refer patients for specialized care if needed. Visits took place at the surgical center, in the participant\'s home, or at central sites ("hubs") located in the rural communities. At each visit, a structured history was taken to detect symptoms of complications, and the wound was inspected. Wound healing was certified when there was an intact healthy scar with no residual exudate or scab formation, and all sutures had been completely absorbed.

Surgery-related adverse events (AEs) were detected at scheduled as well as at unscheduled postoperative visits. Adverse events were predefined and graded as mild, moderate, and severe. (Protocol definitions are available on request.) Grade 1 or mild AEs required no or minimal treatment, whereas grade 2 (moderate) and grade 3 (severe AEs) required medical or surgical intervention. Thus, the moderate and severe AEs are most relevant to assessment of safety. This report focuses on AEs classified as definitely, probably, or possibly related to surgery. The relationship to surgery was in most cases self evident (e.g., bleeding, wound dehiscence, or infection), but in situations where the relationship to surgery was unclear, we erred on the side of caution and assumed a relationship existed. For example, one severe AE requiring hospitalization involved acute severe herpetic ulceration involving the penile shaft and scrotum, but not the surgical wound. This episode occurred during the postoperative period, and it was assumed that surgery precipitated the reactivation of pre-existing herpes. The anatomical site of any lesion was coded as involving the frenulum or other areas of the penis, and codes were added for AEs associated with external causes such as intercourse or trauma.

All surgery-related AEs were reviewed by a medical officer at the time they were reported. The senior urologist (SW), the NIH Medical Officer (MCB), the trial Medical Officer (GK), and the principal investigator (RHG) each independently reviewed all AEs. Subsequently, a panel of physicians, nurses, and clinical officers reviewed all cases and other available records to establish a final diagnosis, severity grading, and assessment of relatedness to surgery. The panel\'s final assignation was achieved by consensus.

Statistical Methods {#s2a}
-------------------

Risks of surgery-related AEs were calculated as the number of men with one or more AEs per 100 surgeries. We also assessed multiple AEs experienced by individual participants and tabulated diagnosis specific rates of AEs graded by severity. Baseline characteristics were compared via chi-squared tests of general association. In comparisons of two proportions, *p*-values were calculated using chi-squared test for equality of two proportions. Exact binomial confidence intervals (CIs) were calculated for risk estimates.

We compared surgery-related AE risks in HIV-positive and HIV-negative men. We also assessed AE risks by sociodemographic characteristics (age, marital status, education, and occupation), risk behaviors (number of sex partners, condom use), and sexually transmitted disease symptoms (GUD, dysuria, and urethral discharge), which differed in frequency between HIV-positive and HIV-negative men at enrollment, and thus potentially could confound the associations between HIV status and the AE outcomes. Adjusted odds ratios (AdjORs) and 95% CIs for all AEs and moderate and severe AEs were estimated by multiple logistic regression. The covariates included in adjusted analyses were age, marital status, education, sex partners in the past year, condom use, and sexually transmitted infection symptoms at enrollment, and initiation of sex before certified wound healing.

We assessed the proportion of men who achieved certified wound healing by 30 postoperative d and at 6 wk following surgery, and evaluated surgery-related AEs among men who reported intercourse prior to certified wound healing, compared with men who resumed intercourse after healing was certified or did not resume sexual activity. Analyses used Intercooled Stata 8 and R.

These trials were reviewed and approved by two Institutional Review Boards (IRBs) in Uganda (The Scientific and Ethics Committee of the Uganda Virus Research Institute, Entebbe, and the AIDS Subcommittee of the National Council on Research and Technology, Kampala) and two IRBs in the US (the Western Institutional Review Board, Bloomberg School of Public Health, Olympia, Washington, and the Johns Hopkins University, Institutional Review Board, Baltimore, Maryland). Each trial was monitored by separate independent DSMBs.

Results {#s3}
=======

[Table 1](#pmed-0050116-t001){ref-type="table"} shows the characteristics of the circumcised HIV-negative and HIV-positive men enrolled in the two trials. The differences in baseline distributions of all these characteristics were statistically significant. The HIV-positive men were substantially older than the HIV-negative men (median ages 32 versus 23 y, respectively), more likely to be married or divorced/separated, and less likely to have secondary or higher education. The HIV-infected men reported having more sexual partners and being less likely to consistently use condoms than the HIV-negative men. Moreover, the HIV-infected men reported higher levels of genital ulceration, urethral discharge, and dysuria.

###### 

Characteristics of HIV-Positive and HIV-Negative Men

![](pmed.0050116.t001)

The follow-up rates at the 4--6-wk postoperative visit were 93.6% for HIV-positive men (393/420) and 96.9% (2,253/2,326) for HIV-negative men. Twenty-five (6.0%) of the HIV-positive men experienced at least one AE, compared to 172 (7.4%) of the HIV-negative men ([Table 2](#pmed-0050116-t002){ref-type="table"}, *p* = 0.29). Only seven of the HIV-positive men (1.7%) and 31 of the HIV-negative men (1.3%) experienced more than one AE, and one HIV-negative man had three AEs. The risks of moderate or severe (grades 2--3) surgery-related AEs were 3.1/100 in the HIV-infected men and 3.5/100 in HIV-negative men (*p* = 0.49). Risks of infections were similar in the two groups, occurring in 2.6% of surgeries in HIV-positive men and in 3.0% of surgeries in uninfected men (*p* = 0.70). Bleeding/hematoma complications were comparable in HIV-positive (1.9%) and HIV-negative men (2.4%, *p* = 0.56). Wound dehiscence was more common among HIV-positive men (2.6%) compared to HIV-negative men (1.3%), and this was statistically significant (*p* = 0.04). Other individual AEs were infrequent, mostly mild, and were comparable in both groups (e.g., pain 0.2% in HIV-positive versus 0.3% in HIV-negative men, and difficulty voiding 0.2% in HIV-positive versus 0.3% in HIV-negative participants).

###### 

Surgery-Related AEs by Severity

![](pmed.0050116.t002)

We estimated the AdjORs of any AE and of moderate/severe AEs by HIV status, controlling for characteristics and behaviors found to differ significantly between the two groups at enrollment ([Table 1](#pmed-0050116-t001){ref-type="table"}), and for initiation of sex before certification of completed wound healing. The AdjOR of any surgery-related AE in HIV-positive men relative to HIV-negative men was 0.79 (95% CI 0.49--1.27), and the AdjOR for moderate or severe AEs was 0.91 (95% CI 0.47--1.74). GUD at enrollment was associated with an increased rate of moderate or severe AEs (odds ratio = 1.68, 95% CI 0.91--3.10, *p* = 0.095), despite the fact that GUDs were treated prior to surgery. No other baseline covariates were found to be associated with moderate/severe AEs.

The median time to wound healing could not be estimated because men were observed at 1 wk and then again at 4--6 wk or thereafter, and completed healing had to precede the scheduled visit at which time the wound was observed and certified. However, follow-up by 30 d postoperatively was available for 393 out of 420 HIV-positive men (93.6%), and 2,258 out of 2,326 HIV-negative men (97.1%). By 30 d following surgery, completed wound healing was certified in 73.0% (287/393) of HIV-positive men, compared with 83.2% (1,879/2,258) of HIV-negative men (*p* \< 0.001), suggesting more rapid wound healing in the HIV-uninfected participants. Men who were not completely healed at 4--6 wk were followed weekly until healing was complete. At 6 wk after surgery, 92.7% (364/393) of HIV-positive and 95.8% (2,163/2,258) of HIV-negative men had complete wound healing certified (*p* = 0.007).

The risks of surgery-related AEs by self-reported timing of intercourse relative to certification of wound healing were assessed ([Table 3](#pmed-0050116-t003){ref-type="table"}). We classified participants as men who initiated intercourse early (≥ 5 d before certification of wound healing), and men who either initiated sex within 5 d of certification or after healing was complete. Among the HIV-positive circumcised participants, 66 (15.7%) reported that they had resumed sex before the wound was certified as healed, whereas among HIV-negative circumcised men, 250 (10.7%) reported resumption of sex before certification of healing. This difference was statistically significant (*p* = 0.003). A higher proportion of HIV-positive men were married, and married men were more likely to resume sex prior to healing certification than were unmarried men. Among 266 HIV-positive currently married men with follow-up information, 74 (27.8%) reported resuming intercourse before wound healing, whereas among 116 HIV-positive unmarried men, 16 (13.8%) resumed sex before healing was certified (*p* = 0.003). Similarly, among 1,047 currently married HIV-negative men, 305 (29.1%) reported resumption of sex before healing, compared to 75 (6.3%) out of 1,182 unmarried men (*p* \< 0.001). Early resumption of intercourse was associated with an increased risk of all surgery-related AEs in HIV-negative and HIV-positive men, although this was statistically significant only for the HIV-uninfected. Early resumption of intercourse prior to wound healing is of programmatic concern because HIV-infected men who resumed sex before wound healing were more likely to infect their female partners (see [Discussion](#s4){ref-type="sec"}) \[[@pmed-0050116-b009]\], so we assessed the frequency of AEs for both groups combined. The AdjOR of any AE associated with resumption of sex before certified wound healing was 1.56 (95% CI 1.05--2.34, *p* = 0.029). However, early resumption of intercourse was not associated with increased moderate or severe AEs (AdjOR = 0.83, 95% CI 0.42--1.63).

###### 

Risks of Surgery-Related AEs by Timing of Resumption of Intercourse in HIV-Positive and HIV-Negative Men

![](pmed.0050116.t003)

We assessed condom use after resumption of sex at an interview 6 mo postenrollment. Among 314 sexually active HIV-positive participants, 53 (16.9%) reported consistent condom use during follow-up compared with 1,755 sexually active HIV-negative men, of whom 330 (18.8%) reported consistent condom use (*p* = 0.42). However, postoperative consistent condom use by the HIV-positive participants during follow-up increased relative to use at enrollment (16.9% versus 7.7%, respectively, *p* \< 0.001). Among HIV-positive men, 45.2% reported inconsistent condom use compared with 37.0% of HIV-negative men (*p* = 0.006).

Discussion {#s4}
==========

We found that the risks of moderate or severe AEs following adult MC were 3.1% in HIV-infected and 3.5% in HIV-negative men. Thus, we conclude that circumcision performed by adequately trained and equipped medical personnel is likely to be safe in HIV-infected men with WHO stage I or II disease and with a CD4 count \> 350 cells/mm^3^. Completed wound healing was more rapid in the HIV-negative than in the HIV-positive men, but over 90% of wounds were certified as completely healed by 6 wk postoperatively. Resumption of intercourse before wound healing was associated with higher rates of surgical complications; thus both circumcised men and their partners should be strongly counseled to delay intercourse until full wound healing is achieved.

It is difficult to compare complication rates following adult MC between the three trials of circumcision for HIV prevention \[[@pmed-0050116-b001]--[@pmed-0050116-b003]\] or case series \[[@pmed-0050116-b007],[@pmed-0050116-b008]\] because of differences in AE definitions, and in methods used for detection of AEs and for reporting of events. Further, with the exception of the three HIV prevention trials reported to date \[[@pmed-0050116-b001]--[@pmed-0050116-b003]\], adult MC is usually performed for medical indications, and the underlying medical conditions (e.g., balanitis, phimosis, ulceration) may contribute to postoperative morbidity. Adult MC complication rates reported in the literature range from 2% to 10% in HIV-negative men \[[@pmed-0050116-b008]\]. Thus, the complication rates observed in the Rakai trial are compatible with rates associated with circumcisions performed by medically trained practitioners elsewhere. Among HIV-negative men, the rates of surgery-related AEs were 1.7% in the Kenyan trial \[[@pmed-0050116-b002]\] (although an earlier publication reported a rate of 3.5% \[[@pmed-0050116-b007]\]), and 3.6% in the South African trial \[[@pmed-0050116-b003]\]. These rates are compatible with moderate and severe events observed in the present study, but lower than the total AEs observed here ([Table 2](#pmed-0050116-t002){ref-type="table"}). However, differences in methods of ascertainment and diagnosis make strict comparisons of AEs between these trials problematic. For example, in the present study in a rural area, AEs were detected by clinical officers mainly during field visits. Review of the AEs suggested that the clinical officers were concerned about access to health services in this setting and tended to overtreat and possibly overdiagnose minor complications. In the South African and Kenyan trials ascertainment of AEs occurred in a central clinic and in settings with better access to services. Thus, the context of the study may have affected reporting. There is little experience with circumcision in HIV-positive adults. The circumcision trial in South Africa reported a surgery-related AE rate of 8.2% in 73 HIV-infected men \[[@pmed-0050116-b003]\], which is similar to the total AE rate of 6.0% observed in the present trial ([Table 2](#pmed-0050116-t002){ref-type="table"}).

The risks of complications following circumcision observed in this and other trials represent the "best case" for safe surgery and were lower than rates of surgical complications observed in public hospitals (11.1%), private medical facilities (22.5%), and traditional practitioners (34.3%) in Kenya \[[@pmed-0050116-b009],[@pmed-0050116-b010]--[@pmed-0050116-b012]\]. High complication rates and deaths have been reported with traditional pubertal circumcision in South Africa \[[@pmed-0050116-b013]\]. Thus, in the scale-up of circumcision programs it will be imperative to provide services under the best feasible circumstances and to upgrade existing personnel and facilities. Efforts will also be required to minimize surgeries by traditional practitioners or to ensure that they have requisite skills.

There is limited experience with the widespread use of surgery as a public health intervention. Mass sterilization programs in India during the 1970s reported serious complications and deaths due to inadequate attention to surgical quality, asepsis, and postoperative care. This led to wide-scale social protest and ultimately rejection of the program \[[@pmed-0050116-b014],[@pmed-0050116-b015]\]. Thus, when circumcision is adopted for HIV prevention, it will be imperative to provide safe surgery and good postoperative care, and to mitigate the possible harm that could arise if traditional procedures are promoted, or if inexperienced medical personnel perform the operation under less than optimal circumstances. Future studies are needed in nonresearch settings to determine the safety of circumcision in programs.

Our finding that complications of circumcision are similar in HIV-positive and HIV-negative men has important programmatic implications. Inclusion of HIV-positive men in future circumcision programs could avoid potential stigmatization and may be of benefit to these men by reducing GUD \[[@pmed-0050116-b009]\]. Although the addition of VCT to circumcision programs is highly desirable, under WHO/UNAIDS guidelines it would not have to be a mandatory precondition for provision of safe surgery \[[@pmed-0050116-b004]\], and this could reduce barriers for persons unwilling to be tested for HIV, as well as reduce the costs and complexity of circumcision services. An additional finding of programmatic relevance is that resumption of sex before completed wound healing was associated with increased AEs, and that wound healing was complete for more than 90% of participants by 6 wk postoperatively. Also, in a separate analysis of male-to-female HIV transmission following circumcision in the Rakai trial, HIV-infected men who resumed intercourse before certified wound healing were more likely to transmit HIV to their initially uninfected female partners \[[@pmed-0050116-b009]\]. This suggests that, if follow-up to certify wound healing cannot be conducted, it would be prudent for programs to recommend sexual abstinence for a minimum of 6 wk after surgery both to avoid complications of surgery and to minimize risks to female partners.

In summary, our findings suggest that circumcision is as safe in HIV-infected men with WHO stage I or II or CD4 counts \> 350 cells/mm^3^, as in uninfected men, and the rates of moderate or severe AEs are acceptably low. However, healing was slower among HIV-positive men, and resumption of intercourse before full wound healing was associated with higher complication rates, irrespective of HIV status, so there is a need to strongly advise men and their female partners of the necessity to abstain from sex until full wound healing is achieved.
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###### Protocol for the Gates Foundation-Funded Trial of MC in HIV-Positive Men

(707 KB DOC)

###### 

Click here for additional data file.

###### Protocol for the NIH Funded Trial of MC for HIV Prevention in HIV-Negative Men

(573 KB DOC)

###### 

Click here for additional data file.
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